Findlay Park Partners LLP Purchases Shares of 461,600 Danaher Corporation $DHR

Findlay Park Partners LLP acquired a new position in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 461,600 shares of the conglomerate’s stock, valued at approximately $87,926,000. Findlay Park Partners LLP owned 0.07% of Danaher at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DHR. BlackRock Inc. purchased a new stake in shares of Danaher during the 2nd quarter valued at about $10,492,520,000. State Street Corp grew its holdings in Danaher by 1.7% during the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the last quarter. Capital International Investors grew its holdings in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Danaher by 9.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after buying an additional 1,334,221 shares during the period. Finally, Wellington Management Group LLP increased its position in Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on DHR shares. Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Wells Fargo & Company cut their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. TD Cowen dropped their price objective on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, Guggenheim dropped their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Price Performance

Danaher stock opened at $219.42 on Friday. The company has a fifty day simple moving average of $195.80 and a 200-day simple moving average of $192.61. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $154.25 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.72 and a beta of 0.78. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period last year, the company posted $0.77 EPS. On average, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.